Overview

Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2006-08-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the activity of subcutaneous (SC) amifostine on the incidence and severity of acute radiochemotherapy-induced esophagitis in patients with unresectable Stage IIIA or IIIB non-small cell lung cancer (NSCLC) receiving combined modality therapy.

Phase:

Phase 2

Details

Lead Sponsor:

MedImmune LLC

Treatments:

Amifostine